Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Gyre Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Gyre Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Weston Claire | Director | – | Aug 4, 2026 | 1 |
| Kirkby Maxwell | Director | – | Aug 4, 2026 | 1 |
| Epstein David M. | Director | – | Jun 30, 2026 | 1 |
| Carmichael Gordon | Director | – | Jun 30, 2026 | 1 |
| Parry Renate | Director | – | Jun 30, 2026 | 1 |
| Nussbaum Rodney L | Director | – | Jun 30, 2026 | 1 |
| Zhang Ping | Director | – | Jun 30, 2026 | 3 |
| Weng Dan | Director | – | Jun 30, 2026 | 1 |
| Ye Weiguo | Chief Operating Officer | 700,000 | Jun 22, 2026 | 8 |
| Luo Ying | Chief Executive Officer | 2,565,226Indirect | Jun 10, 2026 | 2 |
| Bergmann Joshua Benjamin | GC and Corporate Secretary | – | Jun 10, 2026 | 1 |
| GNI Group Ltd. | 10% Owner | 64,005,887Indirect | May 6, 2026 | 1 |
| GNI USA, Inc. | 10% Owner | 64,005,887Indirect | May 6, 2026 | 1 |
| Eastling Thomas Wilson | Chief Financial Officer | 15,000 | May 6, 2026 | 1 |
| Chen Ruoyu | Chief Financial Officer | – | Jan 9, 2026 | 1 |
| Ma Songjiang | President | 2,806,084Indirect | May 29, 2025 | 0 |
| Ying Han | Chief Executive Officer | – | Aug 16, 2024 | 0 |
| Usman Nassim | Director | 1,636 | Jul 1, 2024 | 0 |
| Wu Charles C | Chief Executive Officer | – | Nov 22, 2023 | 0 |
| GNI Hong Kong Ltd | 10% Owner | 0 | Oct 27, 2023 | 0 |
| Lawlor Augustine | Director | 0Indirect | Sep 1, 2023 | 0 |
| Hunt Andrea | Director | 0 | Sep 1, 2023 | 0 |
| Miller Seline E. | SVP Finance; Interim CFO & PAO | 0 | Sep 1, 2023 | 0 |
| Blouse Grant E. | Chief Scientific Officer | 9,417 | Aug 10, 2022 | 0 |
| Williams Eddie | Director | 34,804 | Jan 7, 2022 | 0 |
| Ling Geoffrey M.D. | Director | 31,790 | Jan 7, 2022 | 0 |
| Desouza Errol B | Director | 29,801 | Oct 5, 2021 | 0 |
| Jew Jeanne Y | Director | – | Sep 13, 2021 | 0 |
| Levy Howard | Chief Medical Officer | 639 | Aug 11, 2021 | 0 |
| Tetlow Sharon | Director | – | Jul 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Usman NassimDirector | SSale | −20.0K | $16.15 | −$323.0K | −92.4%1.64K after | 10b5-1 |
| Mar 19, 2024 (view filing) | Mar 15 | 4 days | Usman NassimDirector | SSale | −20.0K | $17.26 | −$345.2K | −92.4%1.64K after | 10b5-1 |
| Oct 31, 2023 (view filing)9:56 PM ET | Oct 27 | 4 days | GNI Group Ltd. and 1 other10% Owner | PPurchase | +811.0K | $4.92 | +$3.99M | –13.2K after | Derivative |
| Oct 31, 2023 (view filing)9:56 PM ET | Oct 27 | 4 days | GNI Group Ltd. and 1 other10% Owner | PPurchaseSeries X Convertible Preferred Stock | +811 | $1,250.05 | +$1.01M | –8.11M after | Derivative |
| Aug 10, 2022 (view filing)5:19 PM ET | Aug 9 | 1 day | Usman NassimPresident & CEO | PPurchase | +3.25K | $0.47 | +$1.53K | +15.3%24.5K after | |
| Aug 10, 2022 (view filing)5:19 PM ET | Aug 9 | 1 day | Miller Seline E.SVP Finance; Interim CFO & PAO | PPurchase | +3.25K | $0.47 | +$1.53K | +100.0%6.50K after | |
| Aug 10, 2022 (view filing)5:17 PM ET | Aug 9 | 1 day | Blouse Grant E.Chief Scientific Officer | PPurchase | +3.25K | $0.47 | +$1.53K | +52.7%9.42K after | |
| Feb 16, 2022 (view filing)8:13 PM ET | Feb 9 | 7 daysLate | Usman NassimPresident & CEO | PPurchase | +3.25K | $0.46 | +$1.50K | +18.0%21.3K after | |
| Feb 16, 2022 (view filing)8:10 PM ET | Feb 9 | 7 daysLate | Miller Seline E.SVP Finance; Interim CFO & PAO | PPurchase | +3.25K | $0.46 | +$1.50K | New position3.25K after | |
| Feb 16, 2022 (view filing)8:07 PM ET | Feb 9 | 7 daysLate | Blouse Grant E.Chief Scientific Officer | PPurchase | +3.25K | $0.46 | +$1.50K | +111.4%6.17K after | |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Usman NassimPresident & CEO | PPurchase | +867 | $3.62 | +$3.14K | +5.0%18.0K after | |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Levy HowardChief Medical Officer | PPurchase | +639 | $3.62 | +$2.31K | New position639 after | |
| Aug 11, 2021 (view filing) | Aug 9 | 2 days | Blouse Grant E.Chief Scientific Officer | PPurchase | +1.16K | $3.62 | +$4.21K | +66.3%2.92K after |